CADL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
23.0M
-14.1%
26.7M
+64.2%
16.3M
+3.4%
15.8M
+19.3%
13.2M
R&D
15.6M
-21.3%
19.8M
+101.2%
9.8M
-10.8%
11.0M
+30.3%
8.5M
SG&A
7.4M
+6.5%
6.9M
+7.8%
6.4M
+36.4%
4.7M
-0.5%
4.7M
Operating Income
-22981000
+14.1%
-26746000
-64.2%
-16284000
-3.4%
-15752000
-19.3%
-13207000
EBITDA
-22810000
+14.2%
-26575000
-64.7%
-16135000
-3.5%
-15589000
-19.8%
-13012000
Net Income
-21873000
+43.8%
-38927000
-339.3%
-8861000
+70.0%
-29496000
-161.7%
-11269000
EPS (Basic)
$-0.28
+46.2%
$-0.52
-271.4%
$-0.14
+74.1%
$-0.54
-157.1%
$-0.21
EPS (Diluted)
$-0.28
+46.2%
$-0.52
-271.4%
$-0.14
+75.9%
$-0.58
-176.2%
$-0.21
Shares (Diluted)
77.4M
+4.4%
74.1M
+18.9%
62.4M
+23.0%
50.7M
-7.7%
54.9M
Candel Therapeutics (CADL) — Financials